PAK2 and Hepatic fibrosis: Our study demonstrated that HUC-MSCs significantly alleviate HSC activation and CCl4-induced liver fibrosis in a mouse model; overexpression of miR-455-3p by targeting PAK2 might be the underlying mechanism for the therapeutic effects of HUC-MSCs in hepatic fibrosis.